# Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

> **NCT07272434** · PHASE3 · RECRUITING · sponsor: **MAXVAX Biotechnology Limited Liability Company** · enrollment: 25000 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
- **BIOLOGICAL:** Placebo (Saline solution)

## Key facts

- **NCT ID:** NCT07272434
- **Lead sponsor:** MAXVAX Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2026-07-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 25000 (ESTIMATED)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07272434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07272434, "Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07272434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*